Hilker, Rolf

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,977

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 919

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 914

Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction

Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell

vaccines and immunoinformatics approachesCancer Immunotherapy and Biomarkers

Cited by 538

Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune Responses

Cited by 31